EMVC
NEUTRALEMV Capital Announces Office Move and Related Party Transaction
The venture capital firm has entered into a licence agreement to share office space with a company owned by a substantial shareholder.
EMV Capital
46.50GBX
1.09%
Market Cap
12.91M
Volume
15.5k
45% of avg
P/E Ratio
-0.08
EPS (TTM)
-6.07
Beta
0.52
Day Range
45.00p - 47.70p
52 Week Range
34.00p46.50p73.00p
46.50p
Upcoming Events
Late June 2026
End of current funding runway
High Impact Event
EMVC
NEUTRALEMV Capital Announces Director Dealings
The asset management firm has announced changes to its major shareholdings.
EMVC
NEUTRALEMV Capital Announces AGM and Annual Report Release
The venture capital firm has released its annual report and announced its upcoming annual general meeting.
EMVC
NEUTRALEMV Capital Directors Increase Shareholdings
The deeptech and life sciences VC investment group announces its CEO and Executive Director have purchased additional shares in the company.
EMVC
BADEMV Capital Reports Widening Losses Amid Challenging Market Conditions
The venture capital firm reported widening losses and faces material uncertainty about its ability to continue as a going concern, despite recent fundraising efforts. Challenging market conditions and limited access to capital continue to pose significant headwinds.
EMVC
NEUTRALEMV Capital Portfolio Company PDS Biotech Reports Q1 2025 Results
The life sciences company reports Q1 2025 financial results and provides an update on its clinical programs and corporate developments.
EMVC
NEUTRALEMV Capital Announces Director Dealings
The asset management firm has announced changes to its major shareholdings.
EMVC
NEUTRALEMV Capital Portfolio Company PDS Biotech Reports Full Year 2024 Results
The life sciences company reports its full year 2024 financial results and provides an update on its clinical programs, including the initiation of a Phase 3 trial for its lead candidate.
EMVC
GOODEMV Capital's Portfolio Company PDS Biotech Advances HPV16-Positive Head and Neck Cancer Therapy to Phase 3 Trial
The deeptech and life sciences VC firm's portfolio company PDS Biotech is advancing its lead immunotherapy candidate into a pivotal Phase 3 trial for a form of head and neck cancer, having cleared the regulatory pathway with the FDA.
EMVC
GOODEMV Capital Backed ProAxsis Announces Progress and Fundraise
The deeptech and life sciences VC firm's portfolio company reports strong financial and operational progress, including 92% revenue growth, reduced losses, and plans for a fundraise to support commercial and clinical development.